eli lilly retatrutide phase 3 trial just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% ESC 2024: Retatrutide improves lipid
Description
We will never ask for a payment or for your credit card number, and we will never ask you to click through a link
Hormone Research in Paediatrics, 70 (1), 5157
doi: 10.1016/j.physbeh.2012.05.015 [DOI] [PMC free article] [PubMed] [Google Scholar] 113.Braniste V, Al-Asmakh M, Kowal C, et al
They have created a form that allows you to write directly to Governor Healey, State Senators, and Representatives
